2018/05/03 To Ease Local Measles Outbreak, MVC Signed MoU with SII

Medigen Vaccine Biologics Corp. (MVC) signed MoU with Serum Institute of India (SII). SII intends to supply MMR vaccine to alleviate Taiwan's current measles outbreak. Both parties aim to supply MMR vaccine for Taiwan's national immunization program in the future.

We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.
Agree